{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:48:30Z","timestamp":1792784910925,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009619","name":"AMED)","doi-asserted-by":"crossref","award":["JP18dm0107119"],"award-info":[{"award-number":["JP18dm0107119"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"name":"China Scholarship Council, China.","id":[{"id":"https:\/\/ror.org\/04atp4p48","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.bbr.2019.111904","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T10:18:26Z","timestamp":1554977906000},"page":"111904","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model"],"prefix":"10.1016","volume":"368","author":[{"given":"Zhongwei","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyu","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijia","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbr.2019.111904_bib0005","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbr.2019.111904_bib0010","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bbr.2019.111904_bib0015","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbr.2019.111904_bib0020","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1017\/S0033291715001506","article-title":"Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial","volume":"45","author":"Murrough","year":"2015","journal-title":"Psychol. Med."},{"key":"10.1016\/j.bbr.2019.111904_bib0025","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1176\/appi.ajp.2015.15040465","article-title":"APA Council of Research Task Force on Novel Biomarkers and Treatments, Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression","volume":"172","author":"Newport","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbr.2019.111904_bib0030","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1017\/S0033291716000064","article-title":"Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories","volume":"46","author":"Kishimoto","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.bbr.2019.111904_bib0035","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyv124","article-title":"Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis","volume":"19","author":"Xu","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.bbr.2019.111904_bib0040","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","article-title":"The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis","volume":"175","author":"Wilkinson","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbr.2019.111904_bib0045","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.conb.2014.12.004","article-title":"Antidepressant actions of ketamine: from molecular mechanisms to clinical practice","volume":"30","author":"Monteggia","year":"2015","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.bbr.2019.111904_bib0050","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1017\/S0033291716000969","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity","volume":"46","author":"Hashimoto","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.bbr.2019.111904_bib0055","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1080\/14728222.2016.1238899","article-title":"Ketamine\u2019s antidepressant action: beyond NMDA receptor inhibition","volume":"20","author":"Hashimoto","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bbr.2019.111904_bib0060","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrd.2017.16","article-title":"Targeting glutamate signaling in depression: progress and prospects","volume":"16","author":"Murrough","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbr.2019.111904_bib0065","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.14344.1","article-title":"Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide","volume":"7","author":"Duman","year":"2018","journal-title":"F1000Res."},{"key":"10.1016\/j.bbr.2019.111904_bib0070","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pharmthera.2018.05.010","article-title":"The neurobiology of depression, ketamine and rapid-acting antidepressants: is it glutamate inhibition or activation?","volume":"190","author":"Abdallah","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbr.2019.111904_bib0075","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bbr.2019.111904_bib0080","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/14737175.2019.1554434","article-title":"An update on ketamine and its two enantiomers as rapid-acting antidepressants","volume":"19","author":"Zhang","year":"2019","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.bbr.2019.111904_bib0085","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pbb.2013.11.033","article-title":"R(-)-ketamine shows greater potency and longer lasting antidepressant effects than S(+)-ketamine","volume":"116","author":"Zhang","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bbr.2019.111904_bib0090","doi-asserted-by":"crossref","first-page":"e632","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.bbr.2019.111904_bib0095","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bbr.2019.111904_bib0100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1124\/jpet.116.239228","article-title":"Antidepressant potential of (R)-Ketamine in rodent models: comparison with (S)-ketamine","volume":"361","author":"Fukumoto","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbr.2019.111904_bib0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2016.12.020","article-title":"(R)-ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R,6R)-hydroxynorketamine","volume":"82","author":"Yang","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbr.2019.111904_bib0110","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/s41398-017-0031-4","article-title":"Possible role of gut-microbiota in the antidepressant effects of (R)-ketamine in a social defeat stress model","volume":"7","author":"Yang","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.bbr.2019.111904_bib0115","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.biopsych.2017.05.016","article-title":"Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model","volume":"83","author":"Yang","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbr.2019.111904_bib0120","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.psychres.2016.03.034","article-title":"Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine","volume":"239","author":"Yang","year":"2016","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.bbr.2019.111904_bib0125","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00406-016-0692-7","article-title":"Reduction of dopamine D2\/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys","volume":"267","author":"Hashimoto","year":"2017","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.bbr.2019.111904_bib0130","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pbb.2018.07.003","article-title":"Expression of heat shock protein HSP-70 in the retrosplenial cortex of rat brain after administration of (R,S)-ketamine and (S)-ketamine, but not (R)-ketamine","volume":"172","author":"Tian","year":"2018","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bbr.2019.111904_bib0135","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0924-977X(96)00042-9","article-title":"Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)","volume":"7","author":"Vollenweider","year":"1997","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bbr.2019.111904_bib0140","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1176\/appi.ajp.2016.16040411","article-title":"Detrimental side effects of repeated ketamine infusions in the brain","volume":"173","author":"Hashimoto","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbr.2019.111904_bib0145","unstructured":"FDA News Release on March 5, 2019. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor\u2019s office or clinic. https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm632761.htm."},{"key":"10.1016\/j.bbr.2019.111904_bib0150","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00406-016-0718-1","article-title":"Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression","volume":"267","author":"Shirayama","year":"2017","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.bbr.2019.111904_bib0155","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/ijnp\/pyx108","article-title":"Lack of antidepressant effects of (2R,6R)-hydroxynorketamine in a rat learned helplessness model: comparison with (R)-ketamine","volume":"21","author":"Shirayama","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.bbr.2019.111904_bib0160","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/ijnp\/pyy053","article-title":"No sex-specific differences in the acute antidepressant actions of (R)-ketamine in an inflammation model","volume":"21","author":"Chang","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.bbr.2019.111904_bib0165","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1038\/s41598-018-22449-9","article-title":"Lack of metabolism in (R)-ketamine\u2019s antidepressant actions in a chronic social defeat stress model","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbr.2019.111904_bib0170","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1007\/s00213-018-5017-2","article-title":"Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model","volume":"235","author":"Zhang","year":"2018","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.bbr.2019.111904_bib0175","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/s41386-018-0084-y","article-title":"(2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice","volume":"43","author":"Yamaguchi","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2019.111904_bib0180","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/ijnp\/pyx120","article-title":"Is metabolism of (R)-ketamine essential for the antidepressant effects?","volume":"21","author":"Chaki","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.bbr.2019.111904_bib0185","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pbb.2018.09.005","article-title":"Now is the time for (2R,6R)-hydroxynorketamine to be viewed independently from its parent drug","volume":"175","author":"Chaki","year":"2018","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bbr.2019.111904_bib0190","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.biopsych.2009.03.016","article-title":"Major depression is a risk factor for low bone mineral density: a meta-analysis","volume":"66","author":"Yirmiya","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbr.2019.111904_bib0195","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00198-009-0918-x","article-title":"Depression and low bone mineral density: a meta-analysis of epidemiological studies","volume":"20","author":"Wu","year":"2009","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bbr.2019.111904_bib0200","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1055\/s-0030-1252020","article-title":"Depression and osteoporosis. A research synthesis with meta-analysis","volume":"42","author":"Cizza","year":"2010","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.bbr.2019.111904_bib0205","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.489","article-title":"Bone density and depressive disorder: a meta-analysis","volume":"6","author":"Schweiger","year":"2016","journal-title":"Brain Behav."},{"key":"10.1016\/j.bbr.2019.111904_bib0210","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1038\/mp.2017.109","article-title":"Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder","volume":"23","author":"Kadriu","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bbr.2019.111904_bib0215","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/ijnp\/pyx100","article-title":"Role of inflammatory bone markers in the antidepressant actions of (R)-ketamine in a chronic social defeat stress model","volume":"21","author":"Zhang","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.bbr.2019.111904_bib0220","doi-asserted-by":"crossref","first-page":"e1138","DOI":"10.1038\/tp.2017.112","article-title":"Blockade of interleukin-6 receptor in the periphery promotes rapid and sustained antidepressant actions: a possible role of gut-microbiota-brain axis","volume":"7","author":"Zhang","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.bbr.2019.111904_bib0225","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.abb.2008.03.018","article-title":"Functions of RANKL\/RANK\/OPG in bone modeling and remodeling","volume":"473","author":"Boyce","year":"2008","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbr.2019.111904_bib0230","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1210\/jc.2007-2325","article-title":"Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study","volume":"93","author":"Ding","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bbr.2019.111904_bib0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2014.06.021","article-title":"Serum interleukin-6 is a predictive biomarker for ketamine\u2019s antidepressant effect in treatment-resistant patients with major depression","volume":"77","author":"Yang","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbr.2019.111904_bib0240","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1084\/jem.182.5.1461","article-title":"Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors","volume":"182","author":"Udagawa","year":"1995","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbr.2019.111904_bib0245","doi-asserted-by":"crossref","first-page":"16876","DOI":"10.1073\/pnas.0604234103","article-title":"Depression induces bone loss through stimulation of the sympathetic nervous system","volume":"103","author":"Yirmiya","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbr.2019.111904_bib0250","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.biopha.2017.01.008","article-title":"Anti-osteoporotic effects of an antidepressant tianeptine on ovariectomized rats","volume":"87","author":"Alkhamees","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbr.2019.111904_bib0255","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.bone.2012.05.018","article-title":"Antidepressant medications and osteoporosis","volume":"51","author":"Rizzoli","year":"2012","journal-title":"Bone"}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432819303146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432819303146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T13:10:22Z","timestamp":1759065022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432819303146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":51,"alternative-id":["S0166432819303146"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2019.111904","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2019.111904","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111904"}}